At the recent ASCO Gastrointestinal Cancers symposium, Cyclacel Ltd. presented preclinical data for the Polo-like kinase 1 (PLK1) inhibitor plogosertib from assessment in models of colorectal cancer.
Theranib Inc. has divulged retinal dehydrogenase 1 (ALDH1A1; RALDH1) and/or retinal dehydrogenase 2 (ALDH1A2; RALDH2) and/or aldehyde dehydrogenase family 1 member A3 (ALDH1A3; RALDH3) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Researchers from Southwest Jiaotong University published the discovery of novel high affinity peptides against the protein of human DNA binding domain of FOXM1 (FOXM1-DBD) to be developed for the treatment of cancer.
Tevogen Bio Holdings Inc. has expanded its relationship with Microsoft Corp. to broaden their AI-focused collaboration and build its Predictcell technology for predictive precision T-cell targeting.
Researchers from Zhengzhou University and affiliated organizations presented the development and preclinical characterization of VVL-12, an oncolytic vaccinia virus (VV) for the treatment of lung cancer.
Swarm Oncology Ltd. has emerged from stealth with a focus on advancing novel T-cell therapies to achieve long-term remission in patients with advanced solid cancers.
Pancreatic cancer has the worst survival rates among all solid tumor types, and its incidence is increasing. Hypoxic conditions that arise from an imbalance between increased oxygen consumption and an inadequate oxygen supply play a key role in several solid tumors. This impacts the proliferation, migration, apoptosis and metabolism of tumor cells; hypoxia is considered a key contributor to chemoresistance in cancer cells.
Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross proceeds of about $126.4 million, assuming a price of $17.25 per share.
RSS
